Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
News|Articles|April 30, 2026
Contemporary OB/GYN's top headlines from April 2026
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor
These are the top 5 headlines you might have missed in April 2026 from Contemporary OB/GYN.
Advertisement
Advertisement
As we get set to move into the month of May 2026, there were several key headlines that Contemporary OB/GYN highlighted, from our several expert interviews, to new data, FDA clearances, and more.
Related to this article
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
The FDA office of Women's Health and Center for Drug Evaluation and Research and hosting a public workshop with a focus on testosterone use in menopausal women.
FDA accepted for review an sNDA for MIUDELLA copper IUD for a 6-year duration, with a PDUFA date in Q2 2027.
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Atogepant reduced perimenstrual migraine days vs. placebo and met all 8 secondary endpoints in the Phase 3 LUNA study.
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Placentas from older mothers held less NAD+, and in aged pregnant mice, nicotinamide riboside or the CD38 inhibitor 78c restored placental NAD+ and improved fetal growth.
Advertisement
Advertisement